Shots:

• Monash University to receive up front along with the research funding during the option period & is also eligible to receive milestones along with royalties based on future net sales if Ono exercises its option
• Monash University’s Biomedicine Discovery Institute will be responsible for the Ab discovery campaign to target two GPCRs traditionally hard to target. Ono to get an exclusive right globally to develop and commercialize existing Abs
• The collaboration combines Monash University’s expertise in anti-GPCR Ab discovery with Ono’s exceptional capabilities in drug development to develop Abs targeting GPCRs for novel therapies in autoimmune and inflammatory diseases

Ref: Ono | Image: Ono

Relatede News:- Genentech Bio Signed a Discovery Collaboration with Kronos Bio to Advance Novel Therapies Against Transcriptional Targets in Oncology